OctreoPharm Sciences
Focused on the development of new radio pharmaceuticals for neuroendocrine tumors.
Launch date
Market cap
-
Enterprise valuation
€20—30m (Dealroom.co estimates Apr 2011.)
Company register number HRB 133718 B (Charlottenburg (Berlin))
Berlin Germany (HQ)
Financials
Estimates*
| EUR | 2010 | 2011 | 2012 |
|---|---|---|---|
| Profit | (<1m) | (1.6m) | (1.1m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
€5.0m | Early VC | ||
€50.0m | Acquisition | ||
| Total Funding | €5.0m | ||
Recent News about OctreoPharm Sciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.